Drug Trial Radar · NCT03038399
Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Last checked: Nov 19, 2026Latest source record: May 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Feb 2, 2017
Primary completion
Apr 30, 2020
Study completion Apr 30, 2020
Sponsor
- Lead sponsor
- ReveraGen BioPharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of Pittsburgh; Cooperative International Neuromuscular Research Group
- First posted
- Jan 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This long-term extension study is an open-label, multiple-dose study to evaluate the long-term safety, tolerability, efficacy and PD of vamorolone administered once daily by liquid oral suspension over a Treatment Period of 24 months to young boys with DMD who participated in the VBP15-002 Phase IIa and VBP15-003 Phase IIa extension core studies.
Conditions
- Duchenne Muscular Dystrophy
Interventions
Vamorolone 0.25 mg/day/dayDrug
Oral administration of 0.25 mg/kg/day daily for 24 months.
Vamorolone 0.75 mg/day/dayDrug
Oral administration of 0.75 mg/kg/day daily for 24 months.
Vamorolone 2.0 mg/day/dayDrug
Oral administration of 2.0 mg/kg/day daily for 24 months.
Vamorolone 6.0 mg/day/dayDrug
Oral administration of 6.0 mg/kg/day daily for 24 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.03Time frame: 24 months
- Total Number of Adverse Events as Assessed by CTCAE Version 4.03Time frame: 24 Months
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
University of California Davis
Davis, California
University of Florida
Gainesville, Florida
Nemours Children's Hospital
Orlando, Florida
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois
Duke University
Durham, North Carolina
University of Texas Southwestern Medical Center
Dallas, Texas
Royal Children's Hospital
Melbourne, Australia
Sydney Children's Hospital
Westmead, Australia
Alberta Children's Hospital
Calgary, Alberta, Canada
Schneider Children's Medical Center
Petah Tikva, Israel
Queen Silvia Children's Hospital
Gothenburg, Sweden
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.